BioSpace News Archive

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the full year and fourth quarter ended December 31, 2023.

Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2023.

Prelude Corporation has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast.

Laser Photonics Corporation announced today that it is attending and sponsoring this year’s Acceleration Summit: National Center for Manufacturing Sciences (NCMS) Technology Showcase.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.

Gemini Bioproducts, LLC today announced the launch of new products designed to improve cell therapy manufacturing processes.

Noramco announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired drug product CDMO, Halo Pharma.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

MediWound Ltd. today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, March 21, 2024.

List Biotherapeutics, Inc. and Sacco System Australia Pty Ltd announced a lead share agreement to introduce and mutually recommend each other’s microbial development and manufacturing services to prospective customers if one party discovers a project that is better suited to the other party’s capability or capacity.